Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer

28 maggio 2026 aggiornato da: Wang Xiaojing, Anhui Provincial Cancer Hospital

Value of Super-Resolution Ultrasound Imaging in Assessing Response to Neoadjuvant Chemotherapy for Breast Cancer: A Prospective Observational Study

  1. Study Design Overview Study Type: Single-center, prospective, observational, diagnostic study. Primary Objective: To validate whether Super-Resolution Ultrasound Imaging (SRUS) can accurately predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer at an early stage (after the first cycle of chemotherapy).

    Sample Size: A total of 150 patients are planned to be enrolled. Study Period: March 2026 - March 2028.

  2. Core Methodology: Cohort Allocation This study employs a classic "Model Development-Validation" cohort design to construct a predictive model and verify its generalizability.

    Allocation Method: Systematic random allocation. Allocation Ratio: 7:3. Randomization: Patients will be assigned based on the sequence of enrollment using a computer-generated random sequence.

    Blinding Principle: Allocation information will be concealed (blinded) from patients and the clinical treatment team. Only the research coordinators and statisticians will have access to the grouping data to prevent information leakage.

    Validation Set (Independent Validation Cohort): Comprising 30% of the sample (45 cases). The data will remain "sealed" until model construction is finalized. It will be used for unbiased, objective performance evaluation of the final model (e.g., calculating AUC, sensitivity).

  3. Study Procedures and Visits

    The study workflow strictly adheres to the chemotherapy timeline, with core data collection points focused on the early phase of treatment:

    V0 (Screening): Confirmation of eligibility criteria. V1 (Baseline, Pre-chemotherapy): Initial SRUS examination to acquire baseline tumor data.

    V2 (Early Visit, 48-72 hours after the 1st cycle): The critical data point for the predictive model; the first follow-up examination.

    V3 (Mid-term Visit, Pre-4th cycle): The second follow-up examination. V4 (Surgery, 3-4 weeks after the last cycle): Radical surgery is performed. V5 (Endpoint Assessment, 2-4 weeks post-surgery): Acquisition of pathological results to confirm pCR status (the gold standard).

  4. Key Technology and Statistics Key Technology: The Mindray Resona A20 ultrasound system will be used in conjunction with Sulfur Hexafluoride (SF6) microbubble contrast agents to extract quantitative parameters such as tumor microvascular density and blood volume.

    Statistical Analysis:

    In the Training Set: LASSO regression will be used for feature selection to construct a logistic regression predictive model.

    In the Validation Set: The formula derived from the training set will be directly applied to calculate the Area Under the ROC Curve (AUC), calibration curves, and other metrics to evaluate model performance.

  5. Eligibility Criteria Inclusion Criteria: Females aged 18-75, histologically confirmed invasive breast cancer, scheduled for standard neoadjuvant chemotherapy, with lesions clearly visible on baseline ultrasound.

Exclusion Criteria: History of prior breast cancer treatment (surgery, radiotherapy, chemotherapy), presence of other active malignancies, pregnancy or lactation, severe organ dysfunction, or poor image quality.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Descrizione dettagliata

Background and Rationale Breast cancer is the most common malignancy among women worldwide. Neoadjuvant chemotherapy (NAC) is standard for locally advanced breast cancer, aiming to downstage tumors and increase surgical options. Conventional imaging modalities (ultrasound, MRI) have limitations in detecting early microvascular changes and residual disease. Super-resolution ultrasound imaging (SRUS) is an emerging technique based on ultrasound localization microscopy, enabling visualization of microvasculature at micron-scale resolution. It provides quantitative parameters including vessel density, blood volume, vascular complexity, perfusion index, and intensity analysis. Preliminary evidence suggests SRUS can detect early microvascular alterations before morphological changes become apparent, but prospective data in breast cancer NAC response prediction are lacking.

Study Design Single-center, prospective, observational, diagnostic study. Patients receive standard NAC per clinical guidelines; no treatment intervention is imposed. The study involves additional SRUS examinations at predefined time points.

Model Development and Validation

Consecutive eligible patients are enrolled and randomly assigned (7:3 ratio using computer-generated sequence) to:

Training set (70%, n=105): for model development, feature selection, and internal optimization.

Validation set (30%, n=45): for independent, unbiased performance validation.

Allocation is concealed from patients and clinical care team. Analysis of SRUS images and pathological assessment are blinded to clinical data and group assignment.

Technical Procedures

Equipment: Mindray Resona A20 ultrasound system, probe frequency 5-18 MHz.

Contrast agent: 4.8 mL sulfur hexafluoride microbubbles (SonoVue) injected intravenously, followed by 5 mL saline flush.

Acquisition: Dynamic image sequences (6 seconds each) are acquired during early arterial phase (10-30 s) and late arterial phase (20-45 s) with breath-holding.

Post-processing: SRIPlatform software extracts quantitative parameters: vessel density, blood volume, vascular complexity, perfusion index, intensity, and velocity. Changes from baseline (Δ%) are calculated.

Study Timeline

V1 (Baseline, within 1 week before NAC): Baseline SRUS.

V2 (Early response, 48-72 hours after cycle 1): First follow-up SRUS (key predictive time point).

V3 (Mid-treatment, before cycle 4): Second follow-up SRUS.

V4 (Surgery, 3-4 weeks after last NAC): Radical breast surgery.

V5 (Pathology, 2-4 weeks post-surgery): Pathological complete response (pCR) determination (reference standard).

Sample Size Based on an assumed pCR rate of 30%, a two-sided 95% confidence interval width of 0.15 for sensitivity (expected 80%), 10% dropout, and 30% allocation to validation set, total enrollment is 150 patients. The training set provides ~32 pCR events, supporting evaluation of 3-5 candidate predictors (event-per-variable rule: 10:1).

Statistical Analysis

Software: R 4.3.0 (glmnet, rms, pROC, rmda).

Variable screening: Univariate analysis (p<0.10), then LASSO regression with 10-fold cross-validation (λ.1se) for dimension reduction.

Model building: Multivariate logistic regression; coefficients, OR, 95% CI.

Internal validation: Bootstrap optimism-corrected AUC.

External validation: Apply final model to validation set; assess discrimination, calibration, and clinical utility (decision curve analysis).

Reporting: Adherence to TRIPOD statement.

Safety and Risk Mitigation SRUS is non-invasive with output within safe limits, equivalent to conventional ultrasound. Risks are minimal (mild discomfort, potential privacy breach). Data are anonymized and stored on encrypted hospital servers.

Quality Control

Standardized operating procedures for image acquisition and post-processing.

Operator training and inter-operator consistency testing.

Image quality review by core laboratory (signal-to-noise ratio, tracking stability, coverage of inflow-washout phases).

100% source data verification for key variables.

Quarterly internal audits.

Ethics and Dissemination Approved by the Institutional Ethics Committee of the First Affiliated Hospital of USTC (West District, Anhui Provincial Cancer Hospital). Conducted in accordance with the Declaration of Helsinki. Written informed consent obtained from all participants. Results will be submitted for publication in peer-reviewed journals regardless of outcome.

Study Period March 2026 - March 2028.

Tipo di studio

Osservativo

Iscrizione (Stimato)

150

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Cina
    • Anhui
      • Hefei, Anhui, Cina, 230001
        • Anhui Provincial Cancer Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

This study will enroll female patients aged 18 to 75 years with histologically confirmed invasive breast cancer who are scheduled to receive neoadjuvant chemotherapy (NAC) prior to surgery.

Participants must have at least one measurable tumor lesion suitable for super-resolution ultrasound imaging. Patients with evidence of distant metastasis (Stage IV) or those who have received prior systemic therapy for the current cancer diagnosis will be excluded.

The study aims to recruit approximately 150 participants from the Anhui Provincial Cancer Hospital. This population represents a typical cohort of locally advanced breast cancer patients undergoing standard NAC protocols.

Descrizione

Inclusion Criteria

  1. Age and Gender: Female patients aged 18 to 75 years.
  2. Diagnosis: Histologically confirmed invasive breast cancer via core needle biopsy.
  3. Treatment Plan: Scheduled to receive standard neoadjuvant chemotherapy at our institution.
  4. Imaging: The lesion is clearly visible on baseline ultrasound. Consent: Willing to participate in the study and sign the written informed consent form.

Exclusion Criteria

  1. Prior Treatment: History of any prior treatment for ipsilateral breast cancer (e.g., surgery, radiotherapy, chemotherapy, or targeted therapy).
  2. Other Malignancies: Presence of other active malignancies.
  3. Pregnancy/Lactation: Pregnant or breastfeeding women.
  4. Health Status: Severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders that preclude cooperation with the examination.
  5. Image Quality: Poor ultrasound image quality that prevents SR-US analysis.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Training set (development queue)
70% of the total sample size (planned to include 105 cases) will be used for constructing predictive models, feature screening (such as using LASSO regression), and internal optimization.
Verification set (independent verification queue)
Training Set (Development Cohort): Participants assigned to this group constitute 70% of the total sample (n=105). Data from this group are used for model development, feature selection, and internal optimization. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team. Validation Set (Independent Validation Cohort): Participants assigned to this group constitute 30% of the total sample (n=45). Data from this group are reserved for unbiased, independent performance validation of the final prediction model. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Discriminative Ability of the Super-Resolution Ultrasound Prediction Model for Pathological Complete Response (pCR)
Lasso di tempo: Through study completion, an average of 24 weeks
The discriminative ability of the final prediction model (derived from super-resolution ultrasound parameters) in identifying pCR, assessed in the independent validation cohort. Performance is quantified by the Area Under the Receiver Operating Characteristic Curve (AUC). An AUC value closer to 1 indicates stronger discriminative ability.
Through study completion, an average of 24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Diagnostic performance of the model.
Lasso di tempo: Through study completion, an average of 24 weeks
In the validation set, the optimal cutoff value is determined using the Youden index. Performance metrics including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are calculated.
Through study completion, an average of 24 weeks
Predictive value of early parameter changes.
Lasso di tempo: 3 weeks
The ability of early changes in super-resolution ultrasound parameters (measured after the first chemotherapy cycle) to predict final pCR status. Evaluated using univariate ROC analysis to calculate the AUC.
3 weeks
Diagnostic Accuracy, Sensitivity, and Specificity of SRUS Model for pCR
Lasso di tempo: Through study completion, an average of 24 weeks
The secondary outcomes include the diagnostic accuracy, sensitivity, and specificity of the SRUS prediction model. These metrics will be calculated based on the confusion matrix derived from the independent validation cohort.
Through study completion, an average of 24 weeks
Clinical utility of the model.
Lasso di tempo: Through study completion, an average of 24 months
The net clinical benefit of using the prediction model to guide clinical decision-making, assessed across a range of threshold probabilities. Evaluated using Decision Curve Analysis (DCA).
Through study completion, an average of 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Anhui Provincial Cancer Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 giugno 2026

Completamento primario (Stimato)

1 marzo 2028

Completamento dello studio (Stimato)

1 luglio 2028

Date di iscrizione allo studio

Primo inviato

7 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 maggio 2026

Primo Inserito (Effettivo)

3 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2026-LLYJ-0025

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro al seno

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Burundi

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi